Trending

rheumatoid arthriitis

RA pill setback spoils Lilly’s growth story

RA pill setback spoils Lilly’s growth story

Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of

X

RA pill setback spoils Lilly’s growth story

https://pharmaphorum.com/news/ra-pill-setback-spoils-lillys-growth-story/

AbbVie looks beyond Humira as RA pill meets phase 3 targets

AbbVie looks beyond Humira as RA pill meets phase 3 targets

Upadacitinib hopes drug will reduce reliance on Humira.

X

AbbVie looks beyond Humira as RA pill meets phase 3 targets

https://pharmaphorum.com/news/abbvie-looks-beyond-humira-ra-pill-meets-phase-3-targets/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com